Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Kroger

Recent Kroger and Biogen picks are looking pretty smart right now.

Berkshire’s Recent Purchases Show Why Value Investing Still Works

Biogen is joining the hunt for a coronavirus treatment with Vir Biotechnology. Further, the company is still working on an Alzheimer's drug.

Biogen Has Entered The Coronavirus Drug Arena — But Is BIIB Stock A Buy?

GW Pharmaceuticals

Vertex Pharmaceuticals

A rebounding stock market lifted all three of these biotech stocks.

Why Biogen, GW Pharmaceuticals, and Vertex Pharmaceuticals Stocks Jumped Today

Sangamo Therapeutics

Sangamo's Partnership With Biogen Is Only One Big Pharma Partnership Based Off Of Pipeline

CAMBRIDGE, Mass., March  16, 2020  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Biogen Foundation has committed $10 million to support global response efforts and communities around the world impacted by the COVID-19 pandemic. The funds will be used to address immediate critical needs, with the majority of donations going to support non-profit organizations in the U.S., including Massachusetts and North Carolina, in Italy and in other impacted countries worldwide. This donation will be used to help expand testing options, ease the strain on medical systems, provide training for front line health workers and support access to necessities like food. This adds to the donation made by Biogen China to the Red Cross Society of China.

Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World

Amgen

CRISPR Therapeutics

Editas Medicine

Gilead Sciences

Innoviva

Regeneron Pharmaceuticals

Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.

7 Biotech Stocks to Buy and Hold in 2020

GlaxoSmithKline

Inovio Pharmaceuticals

Johnson & Johnson

Eli Lilly

Moderna

Vir Biotechnology

While the overall vaccine development process has been impressively fast so far, it might take 12-18 months to fully validate a potential vaccine.

Coronavirus Vaccine Trial Begins, Biotech Competition Heats Up

Both companies offer solid products and pipelines, but only one presents a buy-right-now case.

Better Buy: Biogen vs. Amgen

DexCom

Masimo

In the coronavirus bear market, all stocks are under quarantine. But keep health care stocks Vertex, Biogen, Dexcom, Eli Lilly, Masimo under observation.

Coronavirus Bear Market: All Stocks Are Under Quarantine, But Keep Vertex, Biogen, Dexcom, Eli Lilly, Masimo Under Observation

BioMarin Pharmaceutical

Emergent BioSolutions

Momenta Pharmaceuticals

Mylan

Novavax

An overall market rebound and a presidential press conference carried several biotech and pharmaceutical stocks markedly higher.

Why These Drug Stocks Soared Today

Mallinckrodt PLC

Roche Holding AG

Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.

Coronavirus Drug Development Efforts Pick Up Amid Sell-Off

AbbVie

The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.

Biotech Sector in Focus as Coronavirus Spreads Panic

Arcus Biosciences

Efforts to contain COVID-19 are putting the entire biopharmaceutical industry in a jam.

3 Ways Coronavirus Lockdowns Put Biotech and Big Pharma on Hold

The two biotech companies are still discussing the terms of the deal.

Biogen and Vir Biotechnology to Collaborate to Find a Treatment for the Coronavirus

Shares of Vir Biotechnology Inc. VIR, +12.91% gained 15% in premarket trading on Thursday after it said it intends to partner with Biogen Inc. BIIB, -3.72% to help develop and manufacture its monoclonal antibodies as a potential treatment of COVID-19.

Vir's stock gains 15% as it announces COVID-19 collaboration with Biogen

Microsoft

Takeda Pharmaceutical

Slack

Zoom Video

After a COVID-19 cluster was traced to a Biogen meeting, two big Massachusetts pharmaceutical companies have asked employees to work remotely when possible.

Coronavirus Concerns Have Big Pharma Working From Home

Biogen Inc. BIIB, +0.07% has ordered all of its workers to work from home until further notice, as part of a sweeping round of measures implemented after employees who attended a Boston management meeting tested positive for the coronavirus that causes COVID-19.

Biogen orders all workers to work from home after employees at management meeting test positive for coronavirus

Three Biogen employees tested positive for Covid-19, a new form of coronavirus, after attending a meeting of about 175 people last week in Boston, the biotech company said Friday.
The post Biogen Employees Test Positive For Coronavirus Following Boston Meeting appeared first on Investor's Business Daily.

Biogen Employees Test Positive For Coronavirus Following Boston Meeting

Investors cheer as Biogen wins a patent ruling involving its blockbuster multiple sclerosis drug.

Why Biogen Stock Rose 14.7% in February

With high hopes for the approval of its blockbuster Alzheimer's drug, aducanumab, is now a good time to scoop up Biogen shares?

Biogen Could Score a Major Win if Alzheimer's Drug Gets the Green Light

The partnership would focus on developing treatments for neurological diseases.

Sangamo Therapeutics and Biogen Announce Gene-Therapy Deal, Stock up 39%

Sangamo Therapeutics and Biogen are teaming up to develop several gene therapies, the biotech companies said after the close on Thursday, sending SGMO stock flying in late action.
The post Why This Small Gene Therapy Player Rocketed On A Biogen Deal appeared first on Investor's Business Daily.

Why This Small Gene Therapy Player Rocketed On A Biogen Deal

Many of the larger biotechnology and pharmaceutical companies have changed strategies from making acquisitions of speculative biotech outfits.

Sangamo Partners With Biogen to Target Alzheimer’s and Parkinson’s Development

CAMBRIDGE, Mass. and BRISBANE, Calif., Feb.  27, 2020  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets. The companies will leverage Sangamo’s proprietary zinc finger protein (ZFP) technology delivered via adeno-associated virus (AAV) to modulate the expression of key genes involved in neurological diseases.  

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases

Occidental Petroleum

Buffett doesn’t see many good values in the stock market these days. Could this be an exception?

News for Biogen Stock (BIIB)